Treatment of peanut allergy
AssigneeAllergy Therapeutics (UK) Limited
InventorsMatthias F. Kramer, Andris Zeltins, Murray A. Skinner, Matthew D. Heath
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans.
Claims20
A composition comprising
- (a) a modified virus-like particle (VLP) of cucumber mosaic virus (CMV) with at least one first attachment site, wherein said modified VLP of CMV comprises at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises
- a) a CMV polypeptide, and
- b) a T helper cell epitope, wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, and wherein said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:1,
- wherein said CMV polypeptide comprises
- (i) an amino acid sequence of a coat protein of CMV;
- or
- (ii) an amino acid sequence having a sequence identity of at least 90% to said coat protein of CMV;
- and
- (b) at least one peanut allergen with at least one second attachment site, wherein said peanut allergen consists of a protein consisting of the amino acid sequence of SEQ ID NO:18;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
A composition comprising (a) a modified virus-like particle (VLP) of cucumber mosaic virus (CMV) with at least one first attachment site, wherein said modified VLP of CMV comprises at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises a) a CMV polypeptide, and b) a T helper cell epitope, wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, and wherein said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:1, wherein said CMV polypeptide comprises (i) an amino acid sequence of a coat protein of CMV;
- or (ii) an amino acid sequence having a sequence identity of at least 90% to said coat protein of CMV;
- and (b) at least one peanut allergen with at least one second attachment site, wherein said peanut allergen consists of a protein with the amino acid sequence of SEQ ID NO:
- 22;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
A composition comprising (a) a modified virus-like particle (VLP) of cucumber mosaic virus (CMV) with at least one first attachment site, wherein said modified VLP of CMV comprises at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises a) a CMV polypeptide, and b) a T helper cell epitope, wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, and wherein said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:1, wherein said CMV polypeptide comprises (i) an amino acid sequence of a coat protein of CMV;
- or (ii) an amino acid sequence having a sequence identity of at least 90% to said coat protein of CMV;
- and (b) at least one peanut allergen with at least one second attachment site, wherein said peanut allergen consists of a protein with the amino acid sequence of SEQ ID NO:
- 30;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
Dependencies are inferred from the claim text.